Patent application number | Description | Published |
20090074803 | IMMUNOGEN PLATFORM - Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines. | 03-19-2009 |
20090092631 | GLYCOSYLATED SPECIFICITY EXCHANGERS THAT INDUCE AN ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) RESPONSE - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein. | 04-09-2009 |
20090214593 | IMMUNOGEN PLATFORM - Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines. | 08-27-2009 |
20090215869 | HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE - Aspects of the present invention relate to the creation of mutant hepatitis C virus (HCV) NS3/4A genes encoding proteins with altered protease activity. Embodiments include said NS3/4A genes, HCV peptides encoded by said nucleic acids, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection. | 08-27-2009 |
20100104592 | HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE - Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection. | 04-29-2010 |
20100183635 | GLYCOSYLATED SPECIFICITY EXCHANGERS - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein. | 07-22-2010 |
20100203074 | COMPOSITIONS AND METHODS FOR TREATING INTRACELLULAR DISEASES - The present invention provides methods of treating intracellular infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen, and also administering to the warm-blooded animal a protein which comprises the immunogenic portion of the antigen, such that an immune response is generated. | 08-12-2010 |
20110065174 | HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE - Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection. | 03-17-2011 |
20110081381 | HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE - Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection. | 04-07-2011 |
20110082287 | HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE - Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection. | 04-07-2011 |
20120027795 | SIMPLE VACCINES FROM DNA LAUNCHED SUICIDAL FLAVIVIRUSES - Immunogenic compositions relating to DNA launched suicidal flaviviruses and methods of administering the same are described herein. | 02-02-2012 |
20120039842 | COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE - Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen. | 02-16-2012 |
20120208870 | HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE - Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection. | 08-16-2012 |
20130012865 | CODON-OPTIMZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG) - A needle device for the delivery of therapeutic material into tissue comprising a connection to a pressure generation element, a lumen adapted for the passage of a therapeutic material, and a needle barrel, wherein each needle barrel comprises an opening adapted to control and deliver a pressure transmitted from the pressure generation element into a tissue to cause an increase in the permeability of a cell membrane to the therapeutic material. | 01-10-2013 |
20130041131 | GLYCOSYLATED SPECIFICITY EXCHANGERS - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein. | 02-14-2013 |
20130202554 | COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE - Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen. | 08-08-2013 |
20140081004 | GLYCOSYLATED SPECIFICITY EXCHANGERS - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein. | 03-20-2014 |
20140121587 | INJECTION NEEDLE AND DEVICE - Several needle assemblies and intracellular delivery devices that are used for the delivery of prophylactic and/or therapeutic material (i.e., delivered agents) into a tissue of a subject are disclosed. Preferably, the needle assemblies and/or the intracellular delivery devices comprise needles and/or needle electrodes, which are disposed in an array (e.g., a Y-type array having three outer needles and a center needle), wherein each needle in the array has a closed end and a plurality of apertures along each needle barrel, and the apertures on the needle barrels of the outer needles of the array are positioned to deliver the delivered agent toward the apertures of the center needle and/or an adjacent needle, but not outside of the active zone defined by the area within the needle array and the apertures on the needle barrel of the center needle are positioned to deliver the delivered agent toward the outer needles. | 05-01-2014 |
20140286985 | SIMPLE VACCINES FROM DNA LAUNCHED SUICIDAL FLAVIVIRUSES - Immunogenic compositions relating to DNA launched suicidal flaviviruses and methods of administering the same are described herein. | 09-25-2014 |
20150051388 | IMMUNOGEN PLATFORM - Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines. | 02-19-2015 |